Lupus anticoagulant-hypoprothrombinemia syndrome (SAL-HPT): the pathophysiological paradox between bleeding and thrombosis in the triple-positive antiphospholipid antibody profile and systemic lupus erythematosus
DOI:
https://doi.org/10.32818/reccmi.a10n3a12Keywords:
antipospholipid syndrome, lupus coagulation inhibitor, lupus erythematosus, systemic, hypoprothrombinemias, factor II deficiencyAbstract
The lupus anticoagulant–hypoprothrombinemia syndrome (LAHPS) is a rare entity associated with autoimmune diseases. It may present hemorrhage without a concomitant reduction in thrombotic risk. We report the case of a young male with bleeding as the initial manifestation, associated with systemic lupus erythematosus and triple positive antiphospholipid antibodies profile conferring a high risk of thrombosis. This case posed a therapeutic challenge due to the paradoxical coexistence of hemorrhage and thrombosis. We discuss here medical management in the setting of bleeding, underlying immunologic activity, and the mechanisms responsible for alterations in coagulation times and factor activity.
Downloads
Metrics
References
Omer MH, Salama H, Alghaythi AM, Alharbi AA, AlJohani G. Lupus anticoagulant-hypoprothrombinemia syndrome and pseudotumor cerebri as an initial presentation of systemic lupus erythematosus in a 16-year-old male patient: a case report and literature review. American Journal of Case Reports. 2022; 23. doi: http://dx.doi.org/10.12659/AJCR.938051 (último acceso dic. 2025). DOI: https://doi.org/10.12659/AJCR.938051
Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau A, Haroche J, Frances C, et al. Lupus anticoagulant-hypoprothrom- binemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5): 251-60. DOI: https://doi.org/10.1097/MD.0b013e31826b971f (último acceso dic. 2025). DOI: https://doi.org/10.1097/MD.0b013e31826b971f
Pazzola G, Zuily S, Erkan D. The challenge of bleeding in antiphospholipid antibody-positive patients. Current Rheumatology Reports. 2015; 17(2). doi: https://doi.org/10.1007/s11926-014-0481-0 (último acceso dic. 2025). DOI: https://doi.org/10.1007/s11926-014-0481-0
Mulliez S, F De Keyser, C Verbist, Vantilborgh A, Wijns W, Beukinga I, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus. 2015; 24(7): 736–45. doi: https://doi.org/10.1177/0961203314558859 (último acceso dic. 2025). DOI: https://doi.org/10.1177/0961203314558859
Ahmed AEE. Autoantibodies to coagulation factors and bleeding disorders. Clinical Reviews in Allergy & Immunology. 1998; 16(3): 313–19. doi: https://doi.org/10.1007/BF02737641 (último acceso dic. 2025). DOI: https://doi.org/10.1007/BF02737641
Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology (Amsterdam, Netherlands). 2012; 17 Suppl 1: S153-55. doi: https://doi.org/10.1179/102453312X13336169156654 (último acceso dic. 2025). DOI: https://doi.org/10.1179/102453312X13336169156654
Carvalho C, Viveiro C, Maia P, Rezende T. Acquired antiprothrombin antibodies: an unusual cause of bleeding. Case Reports. 2013; 2013 (jan07 1): bcr2012007948–8. doi: https://doi.org/10.1136/bcr-2012-007948 (último acceso dic. 2025). DOI: https://doi.org/10.1136/bcr-2012-007948
Meireles E, Machado F, Teles L, Chumakova A, Sequeira J, Spínola A. A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome. Journal of Thrombosis and Thrombolysis. 2019; 49(2): 334–36. doi: https://doi.org/10.1007/s11239-019-01955-1 (último acceso dic. 2025). DOI: https://doi.org/10.1007/s11239-019-01955-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Luis Francisco Pineda-Galindo, Giovanni Francisco Domínguez-Quintero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
